How many 8-K filings has Enliven Therapeutics, Inc. filed?

Enliven Therapeutics, Inc. (ELVN) has 9 8-K (Current Event Report) filings on record, spanning Mar 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Enliven Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Enliven Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Enliven Therapeutics, Inc. (ELVN) — 8-K Filings

All 8-K filings from Enliven Therapeutics, Inc.. Browse 9 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (9)

Enliven Therapeutics Announces Executive and Board Changes — Dec 11, 2025 Risk: medium
Enliven Therapeutics, Inc. announced on December 9, 2025, changes in its board and executive team, including the departure of a director and the appointment of
Enliven Therapeutics Files 8-K on Financials — Aug 13, 2025 Risk: low
Enliven Therapeutics, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing also includes financial s
Enliven Therapeutics Files 8-K on Shareholder Vote Matters — Jun 25, 2025 Risk: low
Enliven Therapeutics, Inc. filed an 8-K on June 25, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 24, 2025. The
Enliven Therapeutics Files 8-K for Material Agreement — Jun 16, 2025 Risk: medium
Enliven Therapeutics, Inc. filed an 8-K on June 16, 2025, reporting a material definitive agreement entered into on June 13, 2025. The filing also includes othe
Enliven Therapeutics Files 8-K — Jun 13, 2025 Risk: low
On June 13, 2025, Enliven Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events. No specific
Enliven Therapeutics Files 8-K on Governance and Officer Changes — Jun 18, 2024 Risk: medium
Enliven Therapeutics, Inc. filed an 8-K on June 18, 2024, reporting on several key events. These include the departure of directors or certain officers, the ele
Enliven Therapeutics Files 8-K — Apr 11, 2024 Risk: low
Enliven Therapeutics, Inc. filed an 8-K on April 11, 2024, reporting other events and financial statements. The company, formerly known as IMARA Inc. until Apri
Enliven Therapeutics Files 8-K on Director/Officer Changes — Apr 9, 2024 Risk: low
Enliven Therapeutics, Inc. filed an 8-K on April 9, 2024, reporting changes related to its board of directors and officers, as well as compensatory arrangements
Enliven Therapeutics Files 8-K: Material Agreement & Equity Sales — Mar 19, 2024 Risk: medium
Enliven Therapeutics, Inc. announced on March 19, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of e

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX